参考文献[1]
SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. .
[2]
XiaC, DongX, LiH, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590. .
[3]
AllemaniC, MatsudaT, Di CarloV, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075. .
[4]
ChurchTR, BlackWC, AberleDR, et al. Results of initial low-dose computed tomographic screening for lung cancer[J]. N Engl J Med, 2013, 368(21):1980-1991. .
[5]
WoodDE, KazerooniEA, BaumSL, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(4):412-441. .
[6]
WenderR, FonthamET, BarreraE, et al. American Cancer Society lung cancer screening guidelines[J]. CA Cancer J Clin, 2013, 63(2):107-117. .
[7]
JaklitschMT, JacobsonFL, AustinJH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups[J]. J Thorac Cardiovasc Surg, 2012, 144(1):33-38. .
[8]
KooLC, HoJH. Worldwide epidemiological patterns of lung cancer in nonsmokers[J]. Int J Epidemiol, 1990, 19Suppl 1:S14-S23. .
[9]
ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. .
[10]
Ordóñez-MenaJM, SchöttkerB, MonsU, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium[J]. BMC Med, 2016, 14:62. .
[11]
ChenZM, PetoR, IonaA, et al. Emerging tobacco-related cancer risks in China: a nationwide, prospective study of 0.5 million adults[J]. Cancer, 2015, 121Suppl 17(Suppl 17):3097-3106. .
[12]
PeschB, KendziaB, GustavssonP, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies[J]. Int J Cancer, 2012, 131(5):1210-1219. .
[13]
ObergM, JaakkolaMS, WoodwardA, et al. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries[J]. Lancet, 2011, 377(9760):139-146. .
[14]
JiaPL, ZhangC, YuJJ, et al. The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies[J]. J Cancer Res Clin Oncol, 2018, 144(2):229-240. .
[15]
KimC, GaoYT, XiangYB, et al. Home kitchen ventilation, cooking fuels, and lung cancer risk in a prospective cohort of never smoking women in Shanghai, China[J]. Int J Cancer, 2015, 136(3):632-638. .
[16]
YuIT, ChiuYL, AuJS, et al. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women[J]. Cancer Res, 2006, 66(9):4961-4967. .
[17]
DarbyS, HillD, AuvinenA, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies[J]. BMJ, 2005, 330(7485):223. .
[18]
LammSH, FerdosiH, DissenEK, et al. A systematic review and meta-regression analysis of lung cancer risk and inorganic arsenic in drinking water[J]. Int J Environ Res Public Health, 2015, 12(12):15498-15515. .
[19]
FinchGL, HooverMD, HahnFF, et al. Animal models of beryllium-induced lung disease[J]. Environ Health Perspect, 1996, 104Suppl 5(Suppl 5):973-979. .
[20]
DengY, WangM, TianT, et al. The effect of hexavalent chromium on the incidence and mortality of human cancers: a meta-analysis based on published epidemiological cohort studies[J]. Front Oncol, 2019, 9:24. .
[21]
NawrotT, PlusquinM, HogervorstJ, et al. Environmental exposure to cadmium and risk of cancer: a prospective population-based study[J]. Lancet Oncol, 2006, 7(2):119-126. .
[22]
NgamwongY, TangamornsuksanW, LohitnavyO, et al. Additive synergism between asbestos and smoking in lung cancer risk: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(8):e0135798. .
[23]
Poinen-RughooputhS, RughooputhMS, GuoY, et al. Occupational exposure to silica dust and risk of lung cancer: an updated meta-analysis of epidemiological studies[J]. BMC Public Health, 2016, 16(1):1137. .
[24]
HosgoodHD, WeiH, SapkotaA, et al. Household coal use and lung cancer: systematic review and meta-analysis of case-control studies, with an emphasis on geographic variation[J]. Int J Epidemiol, 2011, 40(3):719-728. .
[25]
HalpennyDF, CunninghamJD, LongNM, et al. Patients with a previous history of malignancy undergoing lung cancer screening: clinical characteristics and radiologic findings[J]. J Thorac Oncol, 2016, 11(9):1447-1452. .
[26]
DaiJ, LvJ, ZhuM, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations[J]. Lancet Respir Med, 2019, 7(10):881-891. .
[27]
Cannon-AlbrightLA, CarrSR, AkerleyW. Population-based relative risks for lung cancer based on complete family history of lung cancer[J]. J Thorac Oncol, 2019, 14(7):1184-1191. .
[28]
AngL, ChanC, YauWP, et al. Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis[J]. Lung Cancer, 2020, 148:129-137. .
[29]
CarrLL, JacobsonS, LynchDA, et al. Features of COPD as predictors of lung cancer[J]. Chest, 2018, 153(6):1326-1335. .
[30]
HongS, MokY, JeonC, et al. Tuberculosis, smoking and risk for lung cancer incidence and mortality[J]. Int J Cancer, 2016, 139(11):2447-2455. .
[31]
JafariNezhadA, YektaKooshaliMH. Lung cancer in idiopathic pulmonary fibrosis: a systematic review and meta-analysis[J]. PLoS One, 2018, 13(8):e0202360. .
[32]
GirouxV, RustgiAK. Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence[J]. Nat Rev Cancer, 2017, 17(10):594-604. .
[33]
YangW, QianF, TengJ, et al. Community-based lung cancer screening with low-dose CT in China: results of the baseline screening[J]. Lung Cancer, 2018, 117:20-26. .
[34]
PastorinoU, SilvaM, SestiniS, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy[J]. Ann Oncol, 2019, 30(7):1162-1169. .
[35]
BeckerN, MotschE, TrotterA, et al. Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial[J]. Int J Cancer, 2020, 146(6):1503-1513. .
[36]
GuisierF, DesleeG, BirembautP, et al. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial[J]. Eur Respir J, 2022, 60(3)..
[37]
ZiegelmayerS, GrafM, MakowskiM, et al. Cost-effectiveness of artificial intelligence support in computed tomography-based lung cancer screening[J]. Cancers (Basel), 2022, 14(7).
[38]
SozziG, BoeriM, RossiM, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study[J]. J Clin Oncol, 2014, 32(8):768-773. .
[39]
SullivanFM, MairFS, AndersonW, et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging[J]. Eur Respir J, 2021, 57(1)..
[40]
ZhangY, LiuW, ZhangH, et al. Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma[J]. Int J Cancer, 2023, 152(7):1490-1500. .
[41]
SeijoLM, PeledN, AjonaD, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges[J]. J Thorac Oncol, 2019, 14(3):343-357. .
[42]
FieldJK, SmithRA, AberleDR, et al. International association for the study of lung cancer computed tomography screening workshop 2011 report[J]. J Thorac Oncol, 2012, 7(1):10-19. .
[43]
SandsJ, TammemägiMC, CouraudS, et al. Lung screening benefits and challenges: a review of the data and outline for implementation[J]. J Thorac Oncol, 2021, 16(1):37-53. .
[44]
NicholsonAG, TsaoMS, BeasleyMB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015[J]. J Thorac Oncol, 2022, 17(3):362-387. .
[45]
RuparelM, QuaifeSL, DicksonJL, et al. Lung screen uptake trial: results from a single lung cancer screening round[J]. Thorax, 2020, 75(10):908-912. .
[46]
Van HalG, Diab GarciaP. Lung cancer screening: targeting the hard to reach-a review[J]. Transl Lung Cancer Res, 2021, 10(5):2309-2322. .
[47]
Van MeerbeeckJP, O′DowdE, WardB, et al. Lung cancer screening: new perspective and challenges in Europe[J]. Cancers (Basel), 2022, 14(9)..
[48]
HenschkeCI, YankelevitzDF, LibbyDM, et al. Survival of patients with stage I lung cancer detected on CT screening[J]. N Engl J Med, 2006, 355(17):1763-1771. .
[49]
SteinertHC. PET and PET-CT of lung cancer[J]. Methods Mol Biol, 2011, 727:33-51. .
[50]
FischerB, LassenU, MortensenJ, et al. Preoperative staging of lung cancer with combined PET-CT[J]. N Engl J Med, 2009, 361(1):32-39. .
[51]
HydeL, HydeCI. Clinical manifestations of lung cancer[J]. Chest, 1974, 65(3):299-306. .
[52]
BonnerJA, SloanJA, RowlandKM, et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer[J]. Clin Cancer Res, 2000, 6(2):597-601.
[53]
PaoneG, De AngelisG, MunnoR, et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1[J]. Eur Respir J, 1995, 8(7):1136-1140. .
[54]
王长利. 肺癌[M]. 北京:科学技术文献出版社, 2009: 24.
[55]
LamyPJ, GrenierJ, KramarA, et al. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer[J]. Lung Cancer, 2000, 29(3):197-203. .
[56]
TakeuchiS, NonakaM, KadokuraM, et al. Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer[J]. Ann Thorac Cardiovasc Surg, 2003, 9(2):98-104.
[57]
BarakV, GoikeH, PanaretakisKW, et al. Clinical utility of cytokeratins as tumor markers[J]. Clin Biochem, 2004, 37(7):529-540. .
[58]
StieberP, DienemannH, HasholznerU, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer[J]. Eur J Clin Chem Clin Biochem, 1993, 31(10):689-694. .
[59]
MolinaR, MarradesRM, AugéJM, et al. Assessment of a combined panel of six serum tumor markers for lung cancer[J]. Am J Respir Crit Care Med, 2016, 193(4):427-437. .
[60]
EttingerDS, WoodDE, AisnerDL, et al. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(4):504-535. .
[61]
WHO Classification of Tumours Editorial Board. WHO classification of tumours. Thoracic Tumours[M]. 5th ed. Lyon: IARC Press, 2021.
[62]
TsaoMS, NicholsonAG, MaleszewskiJJ, et al. Introduction to 2021 WHO classification of thoracic tumors[J]. J Thorac Oncol, 2022, 17(1):e1-e4. .
[63]
TravisWD, DacicS, WistubaI, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy[J]. J Thorac Oncol, 2020, 15(5):709-740. .
[64]
国家肿瘤质控中心肺癌质控专家委员会. 非小细胞肺癌新辅助治疗疗效病理评估专家共识[J]. 中华病理学杂志, 2021, 50(9):1002-1007. .
[65]
TravisWD. Advances in neuroendocrine lung tumors[J]. Ann Oncol, 2010, 21Suppl 7:vii65-vii71. .
[66]
PelosiG, RindiG, TravisWD, et al. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice[J]. J Thorac Oncol, 2014, 9(3):273-284. .
[67]
PelosiG, RodriguezJ, VialeG, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients[J]. Am J Surg Pathol, 2005, 29(2):179-187. .
[68]
FabbriA, CossaM, SonzogniA, et al. Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift[J]. Virchows Arch, 2017, 471(1):31-47. .
[69]
GandhiJS, AlnoorF, SadiqQ, et al. SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma[J]. Pathol Res Pract, 2021, 219:153341. .
[70]
La FleurL, Falk-SörqvistE, SmedsP, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11[J]. Lung Cancer, 2019, 130:50-58. .
[71]
BaineMK, HsiehMS, LaiWV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization[J]. J Thorac Oncol, 2020, 15(12):1823-1835. .
[72]
NonakaD. A study of ΔNp63 expression in lung non-small cell carcinomas[J]. Am J Surg Pathol, 2012, 36(6):895-899. .
[73]
ButnorKJ, BeasleyMB, CaglePT, et al. Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung[J]. Arch Pathol Lab Med, 2009, 133(10):1552-1559. .
[74]
YatabeY, DacicS, BorczukAC, et al. Best Practices recommendations for diagnostic immunohistochemistry in lung cancer[J]. J Thorac Oncol, 2019, 14(3):377-407. .
[75]
KalemkerianGP, NarulaN, KennedyEB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the college of American Pathologists/International Association for the study of lung cancer/association for molecular pathology clinical practice guideline update[J]. J Clin Oncol, 2018, 36(9):911-919. .
[76]
LindemanNI, CaglePT, AisnerDL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology[J]. J Thorac Oncol, 2018, 13(3):323-358. .
[77]
EllisonG, ZhuG, MoulisA, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples[J]. J Clin Pathol, 2013, 66(2):79-89. .
[78]
SacherAG, DahlbergSE, HengJ, et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(3):313-320. .
[79]
WuYL, HerbstRS, MannH, et al. ADAURA: phase iii, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection[J]. Clin Lung Cancer, 2018, 19(4):e533-e536. .
[80]
ZhongWZ, WangQ, MaoWM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19(1):139-148. .
[81]
ZhongWZ, WangQ, MaoWM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase Ⅲ trial[J]. J Clin Oncol, 2021, 39(7):713-722. .
[82]
MokTS, WuYL, ThongprasertS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957. .
[83]
KrisMG, JohnsonBE, BerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA, 2014, 311(19):1998-2006. .
[84]
BarlesiF, MazieresJ, MerlioJP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J]. Lancet, 2016, 387(10026):1415-1426. .
[85]
PaoW, GirardN. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol, 2011, 12(2):175-180. .
[86]
GerberDE, GandhiL, CostaDB. Management and future directions in non-small cell lung cancer with known activating mutations[J]. Am Soc Clin Oncol Educ Book, 2014:e353-e365. .
[87]
JenningsLJ, ArcilaME, CorlessC, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of american pathologists[J]. J Mol Diagn, 2017, 19(3):341-365. .
[88]
EndrisV, PenzelR, WarthA, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing[J]. J Mol Diagn, 2013, 15(6):765-775. .
[89]
HeadSR, KomoriHK, LaMereSA, et al. Library construction for next-generation sequencing: overviews and challenges[J]. Biotechniques, 2014, 56(2):61-64, 66, 68. .
[90]
ShollLM, AisnerDL, AllenTC, et al. Programmed death ligand-1 immunohistochemistry--a new challenge for pathologists: a perspective from members of the pulmonary pathology society[J]. Arch Pathol Lab Med, 2016, 140(4):341-344. .
[91]
RittmeyerA, BarlesiF, WaterkampD, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265. .
[92]
HerbstRS, BaasP, KimDW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550. .
[93]
BorghaeiH, Paz-AresL, HornL, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639. .
[94]
BlasbergJD, PassHI, DoningtonJS. Sublobar resection: a movement from the Lung Cancer Study Group[J]. J Thorac Oncol, 2010, 5(10):1583-1593. .
[95]
NakamuraK, SajiH, NakajimaR, et al. A phase Ⅲ randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)[J]. Jpn J Clin Oncol, 2010, 40(3):271-274. .
[96]
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet, 2014, 383(9928):1561-1571. .
[97]
FordePM, SpicerJ, LuS, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21):1973-1985. .
[98]
GandaraDR, PaulSM, KowanetzM, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9):1441-1448. .
[99]
AurisicchioL, PalloccaM, CilibertoG, et al. The perfect personalized cancer therapy: cancer vaccines against neoantigens[J]. J Exp Clin Cancer Res, 2018, 37(1):86. .
[100]
GinsbergRJ, RubinsteinLV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group[J]. Ann Thorac Surg, 1995, 60(3):615-622; discussion 622-623. .
[101]
VeluswamyRR, EzerN, MhangoG, et al. Limited resection versus lobectomy for older patients with early-stage lung cancer: impact of histology[J]. J Clin Oncol, 2015, 33(30):3447-3453. .
[102]
Rami-PortaR, WittekindC, GoldstrawP. Complete resection in lung cancer surgery: proposed definition[J]. Lung Cancer, 2005, 49(1):25-33. .
[103]
PagèsPB, MordantP, RenaudS, et al. Sleeve lobectomy may provide better outcomes than pneumonectomy for non-small cell lung cancer. A decade in a nationwide study[J]. J Thorac Cardiovasc Surg, 2017, 153(1):184-195.e3. .
[104]
StephensN, RiceD, CorreaA, et al. Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases[J]. Eur J Cardiothorac Surg, 2014, 46(4):607-613. .
[105]
BalduyckB, HendriksJ, LauwersP, et al. Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy[J]. J Thorac Oncol, 2008, 3(6):604-608. .
[106]
MaZ, DongA, FanJ, et al. Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis[J]. Eur J Cardiothorac Surg, 2007, 32(1):20-28. .
[107]
ShiW, ZhangW, SunH, et al. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis[J]. World J Surg Oncol, 2012, 10:265. .
[108]
AltorkiN, WangX, KozonoD, et al. Lobar or sublobar resection for peripheral stage ⅠA non-small-cell lung cancer[J]. N Engl J Med, 2023, 388(6):489-498. .
[109]
SuzukiK, SajiH, AokageK, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial[J]. J Thorac Cardiovasc Surg, 2019, 158(3):895-907. .
[110]
AokageK, SuzukiK, SajiH, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial[J]. Lancet Respir Med, 2023, 11(6):540-549. .
[111]
KoikeT, KitaharaA, SatoS, et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer[J]. Ann Thorac Surg, 2016, 101(4):1354-1360. .
[112]
SuzukiK, WatanabeSI, WakabayashiM, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer[J]. J Thorac Cardiovasc Surg, 2022, 163(1):289-301.e2. .
[113]
PetrellaF, SpaggiariL. Therapeutic options following pneumonectomy in non-small cell lung cancer[J]. Expert Rev Respir Med, 2016, 10(8):919-925. .
[114]
ZhangW, WeiY, JiangH, et al. Video-assisted thoracoscopic surgery versus thoracotomy lymph node dissection in clinical stage Ⅰ lung cancer: a meta-analysis and system review[J]. Ann Thorac Surg, 2016, 101(6):2417-2424. .
[115]
BendixenM, JørgensenOD, KronborgC, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial[J]. Lancet Oncol, 2016, 17(6):836-844. .
[116]
OsarogiagbonRU, DeckerPA, BallmanK, et al. Survival implications of variation in the thoroughness of pathologic lymph node examination in American College of Surgeons Oncology Group Z0030 (Alliance)[J]. Ann Thorac Surg, 2016, 102(2):363-369. .
[117]
DarlingGE, AllenMS, DeckerPA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial[J]. J Thorac Cardiovasc Surg, 2011, 141(3):662-670. .
[118]
HowingtonJA, BlumMG, ChangAC, et al. Treatment of stage Ⅰ and Ⅱ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5Suppl):e278S-e313S. .
[119]
EdwardsJG, ChanskyK, Van SchilP, et al. The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer[J]. J Thorac Oncol, 2020, 15(3):344-359. .
[120]
PostmusPE, KerrKM, OudkerkM, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv1-iv21. .
[121]
ArriagadaR, AuperinA, BurdettS, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data[J]. Lancet, 2010, 375(9722):1267-1277. .
[122]
WakeleeHA, DahlbergSE, KellerSM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1610-1623. .
[123]
StraussGM, HerndonJE, MaddausMA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage ⅠB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups[J]. J Clin Oncol, 2008, 26(31):5043-5051. .
[124]
ButtsCA, DingK, SeymourL, et al. Randomized phase Ⅲ trial of vinorelbine plus cisplatin compared with observation in completely resected stage ⅠB and Ⅱ non- small-cell lung cancer: updated survival analysis of JBR-10[J]. J Clin Oncol, 2010, 28(1):29-34. .
[125]
QianF, YangW, WangR, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage ⅠB lung adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2018, 155(3):1227-1235.e2. .
[126]
BradleyJD, PaulusR, GrahamMV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage Ⅱ and ⅢA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705[J]. J Clin Oncol, 2005, 23(15):3480-3487. .
[127]
TateishiY, HoritaN, NamkoongH, et al. Postoperative radiotherapy for completely resected Masaoka/Masaoka-Koga stage Ⅱ/Ⅲ thymoma improves overall survival: an updated meta-analysis of 4746 patients[J]. J Thorac Oncol, 2021, 16(4):677-685. .
[128]
DouillardJY, RosellR, De LenaM, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage Ⅰ, Ⅱ, or ⅢA non-small- cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial[J]. Int J Radiat Oncol Biol Phys, 2008, 72(3):695-701. .
[129]
KrisMG, GasparLE, ChaftJE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update[J]. J Clin Oncol, 2017, 35(25):2960-2974. .
[130]
WuYL, TsuboiM, HeJ, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18):1711-1723. .
[131]
HeJ, SuC, LiangW, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9):1021-1029. .
[132]
FelipE, AltorkiN, ZhouC, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non- small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308):1344-1357. .
[133]
GhiribelliC, VoltoliniL, PaladiniP, et al. Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump[J]. Eur J Cardiothorac Surg, 1999, 16(5):555-559. .
[134]
ParkHJ, ParkHS, ChaYJ, et al. Efficacy of adjuvant chemotherapy for completely resected stage ⅠB non-small cell lung cancer: a retrospective study[J]. J Thorac Dis, 2018, 10(4):2279-2287. .
[135]
WisniveskyJP, SmithCB, PackerS, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages Ⅱ-ⅢA lung cancer: observational cohort study[J]. BMJ, 2011, 343:d4013. .
[136]
ZhouM, LiT, LiuY, et al. Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer[J]. BMC Cancer, 2015, 15:36. .
[137]
KozowerBD, LarnerJM, DetterbeckFC, et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5Suppl):e369S-e399S. .
[138]
LeventakosK, PeikertT, MidthunDE, et al. Management of multifocal lung cancer: results of a survey[J]. J Thorac Oncol, 2017, 12(9):1398-1402. .
[139]
TanvetyanonT, FinleyDJ, FabianT, et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data[J]. Ann Oncol, 2013, 24(4):889-894. .
[140]
BrunelliA, CharlouxA, BolligerCT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)[J]. Eur Respir J, 2009, 34(1):17-41. .
[141]
PignonJP, TribodetH, ScagliottiGV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21):3552-3559. .
[142]
FiratS, ByhardtRW, GoreE. Comorbidity and Karnofksy performance score are independent prognostic factors in stage Ⅲ non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2002, 54(2):357-364. .
[143]
ColinetB, JacotW, BertrandD, et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson′s index[J]. Br J Cancer, 2005, 93(10):1098-1105. .
[144]
CharlsonM, SzatrowskiTP, PetersonJ, et al. Validation of a combined comorbidity index[J]. J Clin Epidemiol, 1994, 47(11):1245-1251. .
[145]
EberhardtWE, De RuysscherD, WederW, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage Ⅲ non-small-cell lung cancer[J]. Ann Oncol, 2015, 26(8):1573-1588. .
[146]
BoffaDJ, HancockJG, YaoX, et al. Now or later: evaluating the importance of chemotherapy timing in resectable stage Ⅲ (N2) lung cancer in the National Cancer Database[J]. Ann Thorac Surg, 2015, 99(1):200-208. .
[147]
LimE, HarrisG, PatelA, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials[J]. J Thorac Oncol, 2009, 4(11):1380-1388. .
[148]
GrahamAN, ChanKJ, PastorinoU, et al. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 1999, 117(2):246-251. .
[149]
De LeynP, LardinoisD, Van SchilPE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2007, 32(1):1-8. .
[150]
WederW, CollaudS, EberhardtWE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage Ⅲ non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg, 2010, 139(6):1424-1430. .
[151]
KimAW, BoffaDJ, WangZ, et al. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2012, 143(1):55-63. .
[152]
CurranWJ, PaulusR, LangerCJ, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: randomized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst, 2011, 103(19):1452-1460. .
[153]
AupérinA, Le PéchouxC, RollandE, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-2190. .
[154]
RamnathN, DillingTJ, HarrisLJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5Suppl):e314S-e340S. .
[155]
BradleyJ, BaeK, ChoiN, et al. A phase Ⅱ comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):435-441.e1. .
[156]
Sanuki-FujimotoN, SumiM, ItoY, et al. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses[J]. Radiother Oncol, 2009, 91(3):433-437. .
[157]
KongFM, Ten HakenRK, SchipperM, et al. Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial[J]. JAMA Oncol, 2017, 3(10):1358-1365. .
[158]
MauguenA, Le PéchouxC, SaundersMI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis[J]. J Clin Oncol, 2012, 30(22):2788-2797. .
[159]
BradleyJD, PaulusR, KomakiR, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2):187-199. .
[160]
ChunSG, HuC, ChoyH, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial[J]. J Clin Oncol, 2017, 35(1):56-62. .
[161]
HannaN, NeubauerM, YiannoutsosC, et al. Phase Ⅲ study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage Ⅲ non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology[J]. J Clin Oncol, 2008, 26(35):5755-5760. .
[162]
WangL, WuS, OuG, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage Ⅲ non-small cell lung cancer[J]. Lung Cancer, 2012, 77(1):89-96. .
[163]
GovindanR, BogartJ, StinchcombeT, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407[J]. J Clin Oncol, 2011, 29(23):3120-3125. .
[164]
SauseW, KolesarP, TaylorS IV, et al. Final results of phase Ⅲ trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group[J]. Chest, 2000, 117(2):358-364. .
[165]
BelderbosJ, UitterhoeveL, van ZandwijkN, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)[J]. Eur J Cancer, 2007, 43(1):114-121. .
[166]
TanEH, SzczesnaA, KrzakowskiM, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer[J]. Lung Cancer, 2005, 49(2):233-240. .
[167]
DaweDE, ChristiansenD, SwaminathA, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage Ⅲ non-small cell lung cancer: a systematic review and meta-analysis[J]. Lung Cancer, 2016, 99:180-185. .
[168]
SigelK, LurslurchachaiL, BonomiM, et al. Effectiveness of radiation therapy alone for elderly patients with unresected stage Ⅲ non-small cell lung cancer[J]. Lung Cancer, 2013, 82(2):266-270. .
[169]
CardenalF, NadalE, JovéM, et al. Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage Ⅲ non-small-cell lung cancer: a review of the literature[J]. Ann Oncol, 2015, 26(2):278-288. .
[170]
VokesEE, HerndonJE, KelleyMJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage Ⅲ Non-small-cell lung cancer: Cancer and Leukemia Group B[J]. J Clin Oncol, 2007, 25(13):1698-1704. .
[171]
SocinskiMA, BlackstockAW, BogartJA, et al. Randomized phase Ⅱ trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105[J]. J Clin Oncol, 2008, 26(15):2457-2463. .
[172]
SauseWT, ScottC, TaylorS, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase Ⅲ trial in regionally advanced, unresectable non-small-cell lung cancer[J]. J Natl Cancer Inst, 1995, 87(3):198-205. .
[173]
HuiR, ÖzgüroğluM, VillegasA, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage Ⅲ, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(12):1670-1680. .
[174]
ZhouQ, ChenM, JiangO, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(2):209-219. .
[175]
TsujinoK, KurataT, YamamotoS, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature[J]. J Thorac Oncol, 2013, 8(9):1181-1189. .
[176]
MokT, WuYL, KudabaI, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830. .
[177]
SoriaJC, OheY, VansteenkisteJ, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2):113-125. .
[178]
RamalingamSS, VansteenkisteJ, PlanchardD, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2020, 382(1):41-50. .
[179]
LuS, DongX, JianH, et al. AENEAS: A randomized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27):3162-3171. .
[180]
ShiY, ChenG, WangX, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir Med, 2022, 10(11):1019-1028. .
[181]
InoueA, KobayashiK, MaemondoM, et al. Updated overall survival results from a randomized phase Ⅲ trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)[J]. Ann Oncol, 2013, 24(1):54-59. .
[182]
MitsudomiT, MoritaS, YatabeY, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2):121-128. .
[183]
ZhouC, WuYL, ChenG, et al. Final overall survival results from a randomised, phase Ⅲ study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)[J]. Ann Oncol, 2015, 26(9):1877-1883. .
[184]
ShiYK, WangL, HanBH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 28(10):2443-2450. .
[185]
WuYL, ZhouC, HuCP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2):213-222. .
[186]
ParkK, TanEH, O′ByrneK, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589. .
[187]
MokTS, ChengY, ZhouX, et al. Improvement in Overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. J Clin Oncol, 2018, 36(22):2244-2250. .
[188]
SaitoH, FukuharaT, FuruyaN, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5):625-635. .
[189]
ChengY, MurakamiH, YangPC, et al. Randomized phase Ⅱ trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations[J]. J Clin Oncol, 2016, 34(27):3258-3266. .
[190]
HanB, JinB, ChuT, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial[J]. Int J Cancer, 2017, 141(6):1249-1256. .
[191]
YangJC, SequistLV, GeaterSL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7):830-838. .
[192]
ShawAT, BauerTM, de MarinisF, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer[J]. N Engl J Med, 2020, 383(21):2018-2029. .
[193]
HornL, WangZ, WuG, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial[J]. JAMA Oncol, 2021, 7(11):1617-1625. .
[194]
HidaT, NokiharaH, KondoM, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial[J]. Lancet, 2017, 390(10089):29-39. .
[195]
ZhouC, KimSW, ReungwetwattanaT, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study[J]. Lancet Respir Med, 2019, 7(5):437-446. .
[196]
SoriaJC, TanD, ChiariR, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072):917-929. .
[197]
CamidgeDR, KimHR, AhnMJ, et al. Brigatinib versus crizotinib in alk inhibitor-naive advanced alk-positivE NSCLC: final results of phase 3 ALTA-1L trial[J]. J Thorac Oncol, 2021, 16(12):2091-2108. .
[198]
SolomonBJ, MokT, KimDW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23):2167-2177. .
[199]
ShawAT, OuSH, BangYJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 371(21):1963-1971. .
[200]
DziadziuszkoR, KrebsMG, De BraudF, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer[J]. J Clin Oncol, 2021, 39(11):1253-1263. .
[201]
YuY, ZhouJ, LiX, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial[J]. EClinicalMedicine, 2023, 59:101952. .
[202]
LuS, FangJ, LiX, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med, 2021, 9(10):1154-1164. .
[203]
PlanchardD, SmitEF, GroenH, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial[J]. Lancet Oncol, 2017, 18(10):1307-1316. .
[204]
DrilonA, OxnardGR, TanD, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(9):813-824. .
[205]
ReckM, Rodríguez-AbreuD, RobinsonAG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. J Clin Oncol, 2019, 37(7):537-546. .
[206]
ReckM, Rodríguez-AbreuD, RobinsonAG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. .
[207]
HerbstRS, GiacconeG, de MarinisF, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14):1328-1339. .
[208]
GandhiL, Rodríguez-AbreuD, GadgeelS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092. .
[209]
NishioM, BarlesiF, WestH, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial[J]. J Thorac Oncol, 2021, 16(4):653-664. .
[210]
ZhouC, ChenG, HuangY, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305-314. .
[211]
YangY, WangZ, FangJ, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology program by innovENT anti-PD-1-11)[J]. J Thorac Oncol, 2020, 15(10):1636-1646. .
[212]
LuS, WangJ, YuY, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial[J]. J Thorac Oncol, 2021, 16(9):1512-1522. .
[213]
ZhouC, WangZ, SunY, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial[J]. Lancet Oncol, 2022, 23(2):220-233. .
[214]
WangZ, WuL, LiB, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)[J]. J Clin Oncol, 2023, 41(3):651-663. .
[215]
秦叔逵, 程颖, 李进, 等. 洛铂联合紫杉醇与卡铂联合紫杉醇一线治疗局部晚期或转移性非小细胞肺癌有效性和安全性的随机、对照、多中心Ⅲ期临床研究[J]. 临床肿瘤学杂志, 2018, 23(3):193-199. .
[216]
RollinsKD, LindleyC. Pemetrexed: a multitargeted antifolate[J]. Clin Ther, 2005, 27(9):1343-1382. .
[217]
HannaN, ShepherdFA, FossellaFV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004, 22(9):1589-1597. .
[218]
LangerCJ, LeightonJC, ComisRL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase Ⅱ toxicity, response, and survival analysis[J]. J Clin Oncol, 1995, 13(8):1860-1870. .
[219]
ShiM, GuA, TuH, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase Ⅲ trial[J]. Ann Oncol, 2021, 32(1):85-96. .
[220]
OheY, OhashiY, KubotaK, et al. Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan[J]. Ann Oncol, 2007, 18(2):317-323. .
[221]
ScagliottiGV, ParikhP, von PawelJ, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21):3543-3551. .
[222]
FossellaF, PereiraJR, von PawelJ, et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group[J]. J Clin Oncol, 2003, 21(16):3016-3024. .
[223]
FløttenØ, GrønbergBH, BremnesR, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase Ⅲ randomised controlled trial by the Norwegian Lung Cancer Study Group[J]. Br J Cancer, 2012, 107(3):442-447. .
[224]
PassardiA, CecconettoL, Dall′agataM, et al. Randomized phase Ⅱ study with two gemcitabine-and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer[J]. J Transl Med, 2008, 6:65. .
[225]
ChiapporiA, SimonG, WilliamsC, et al. Phase Ⅱ study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer[J]. Oncology, 2005, 68(4-6):382-390. .
[226]
SandlerA, GrayR, PerryMC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006, 355(24):2542-2550. .
[227]
HanB, XiuQ, WangH, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(6):1104-1109. .
[228]
Paz-AresLG, de MarinisF, DediuM, et al. PARAMOUNT: final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31(23):2895-2902. .
[229]
GridelliC, de MarinisF, ThomasM, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase Ⅲ study[J]. J Thorac Oncol, 2014, 9(7):991-997. .
[230]
BrodowiczT, KrzakowskiM, ZwitterM, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J]. Lung Cancer, 2006, 52(2):155-163. .
[231]
PérolM, ChouaidC, PérolD, et al. Randomized, phase Ⅲ study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non‐small‐cell lung cancer[J]. J Clin Oncol, 2012, 30(28): 3516‐3524. .
[232]
KostyMP, WozniakAJ, JahanzebM, et al. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study[J]. Target Oncol, 2015, 10(4):509-516. .
[233]
CiuleanuT, BrodowiczT, ZielinskiC, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study[J]. Lancet, 2009, 374(9699):1432-1440. .
[234]
Paz-AresL, LuftA, VicenteD, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. .
[235]
WangJ, LuS, YuX, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(5):709-717. .
[236]
ZhouC, WuL, FanY, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)[J]. J Thorac Oncol, 2021, 16(9):1501-1511. .
[237]
ShukuyaT, YamanakaT, SetoT, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2015, 16(16):1630-1638. .
[238]
SchillerJH, HarringtonD, BelaniCP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98. .
[239]
SocinskiMA, BondarenkoI, KarasevaNA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(17):2055-2062. .
[240]
WangZ, HuangC, YangJJ, et al. A randomised phase Ⅱ clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)[J]. Eur J Cancer, 2019, 109:183-191. .
[241]
RenS, ChenJ, XuX, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial[J]. J Thorac Oncol, 2022, 17(4):544-557. .
[242]
HanB, TjulandinS, HagiwaraK, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study[J]. Lung Cancer, 2017, 113:37-44. .
[243]
ZhouC, RamalingamSS, KimTM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(12):e214761. .
[244]
XuQ, ZhouF, LiuH, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs[J]. J Thorac Oncol, 2018, 13(9):1383-1392. .
[245]
MokTS, Y-LW, M-JA, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7):629-640. .
[246]
LuS, WangQ, ZhangG, et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+NSCLC: updated post-national medical products administration approval results from the APOLLO Registrational Trial[J]. J Thorac Oncol, 2022, 17(3):411-422. .
[247]
ShiY, HuX, ZhangS, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study[J]. Lancet Respir Med, 2021, 9(8):829-839. .
[248]
HanB, LiK, WangQ, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11):1569-1575. .
[249]
WeickhardtAJ, ScheierB, BurkeJM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer[J]. J Thorac Oncol, 2012, 7(12):1807-1814. .
[250]
OuSH, JännePA, BartlettCH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC[J]. Ann Oncol, 2014, 25(2):415-422. .
[251]
LuS, ZhouQ, LiuX, et al. Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in people′s republic of China[J]. J Thorac Oncol, 2022, 17(6):816-826. .
[252]
NovelloS, MazièresJ, OhIJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase Ⅲ ALUR study[J]. Ann Oncol, 2018, 29(6):1409-1416. .
[253]
ShawAT, KimTM, CrinòL, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(7):874-886. .
[254]
YangY, ZhouJ, ZhouJ, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial[J]. Lancet Respir Med, 2020, 8(1):45-53. .
[255]
HuberRM, HansenKH, Paz-Ares RodríguezL, et al. Brigatinib in crizotinib-refractory ALK+NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial[J]. J Thorac Oncol, 2020, 15(3):404-415. .
[256]
ShawAT, VargheseAM, SolomonBJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer[J]. Ann Oncol, 2013, 24(1):59-66. .
[257]
LeeHY, AhnHK, JeongJY, et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer[J]. Lung Cancer, 2013, 79(1):40-45. .
[258]
DrilonA, ChiuCH, FanY, et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC[J]. JTO Clin Res Rep, 2022, 3(6):100332. .
[259]
GainorJF, CuriglianoG, KimDW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study[J]. Lancet Oncol, 2021, 22(7):959-969. .
[260]
DemetriGD, De BraudF, DrilonA, et al. Correction: updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors[J]. Clin Cancer Res, 2022, 28(10):2196. .
[261]
DrilonA, LaetschTW, KummarSet al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children[J]. N Engl J Med2018; 378 (8): 731-739. .
[262]
WuYL, LuS, ChengY, et al. Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5):867-875. .
[263]
ShepherdFA, DanceyJ, RamlauR, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J]. J Clin Oncol, 2000, 18(10):2095-2103. .
[264]
BrahmerJ, ReckampKL, BaasP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135. .
[265]
KudererNM, DaleDC, CrawfordJ, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review[J]. J Clin Oncol, 2007, 25(21):3158-3167. .
[266]
AndrewsDW, ScottCB, SperdutoPW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial[J]. Lancet, 2004, 363(9422):1665-1672. .
[267]
PatchellRA, TibbsPA, WalshJW, et al. A randomized trial of surgery in the treatment of single metastases to the brain[J]. N Engl J Med, 1990, 322(8):494-500. .
[268]
VechtCJ, Haaxma-ReicheH, NoordijkEM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?[J]. Ann Neurol, 1993, 33(6):583-590. .
[269]
NoordijkEM, VechtCJ, Haaxma-ReicheH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age[J]. Int J Radiat Oncol Biol Phys, 1994, 29(4):711-717. .
[270]
RossiNP, ZavalaDC, VanGilderJC. A combined surgical approach to non-oat-cell pulmonary carcinoma with single cerebral metastasis[J]. Respiration, 1987, 51(3):170-178. .
[271]
SchuchertMJ, LuketichJD. Solitary sites of metastatic disease in non-small cell lung cancer[J]. Curr Treat Options Oncol, 2003, 4(1):65-79. .
[272]
YukselC, BozkurtM, YenigunBM, et al. The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: results of a single center retrospective study[J]. Thorac Cardiovasc Surg, 2014, 62(7):605-611. .
[273]
SundaresanN, GalicichJH. Surgical treatment of single brain metastases from non-small-cell lung cancer[J]. Cancer Invest, 1985, 3(2):107-113. .
[274]
TorreM, BarbieriB, BeraE, et al. Surgical therapy in lung cancer with single brain metastasis[J]. Eur J Cardiothorac Surg, 1988, 2(5):336-339. .
[275]
BillingsJA, FerrisFD, MacdonaldN, et al. The role of palliative care in the home in medical education: report from a national consensus Conference[J]. J Palliat Med, 2001, 4(3):361-371. .
[276]
GranoneP, MargaritoraS, D′AndrilliA, et al. Non-small cell lung cancer with single brain metastasis: the role of surgical treatment[J]. Eur J Cardiothorac Surg, 2001, 20(2):361-366. .
[277]
AmbrogiV, ToniniG, MineoTC. Prolonged survival after extracranial metastasectomy from synchronous resectable lung cancer[J]. Ann Surg Oncol, 2001, 8(8):663-666. .
[278]
RazDJ, LanutiM, GaissertHC, et al. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma[J]. Ann Thorac Surg, 2011, 92(5):1788-1792; discussion 1793. .
[279]
PlönesT, Osei-AgyemangT, KrohnA, et al. Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer[J]. Indian J Surg, 2015, 77(Suppl 2):216-220. .
[280]
PorteH, SiatJ, GuibertB, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study[J]. Ann Thorac Surg, 2001, 71(3):981-985. .
[281]
MordantP, ArameA, De DominicisF, et al. Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?[J]. Eur J Cardiothorac Surg, 2012, 41(3):617-622. .
[282]
XuQ, WangY, LiuH, et al. Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis[J]. Clin Transl Oncol, 2013, 15(10):802-809. .
[283]
CollenC, ChristianN, SchallierD, et al. Phase Ⅱ study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients[J]. Ann Oncol, 2014, 25(10):1954-1959. .
[284]
De RuysscherD, WandersR, van BaardwijkA, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)[J]. J Thorac Oncol, 2012, 7(10):1547-1555. .
[285]
De PasTM, de BraudF, CatalanoG, et al. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era[J]. Ann Thorac Surg, 2007, 83(1):231-234. .
[286]
OuyangWW, SuSF, MaZ, et al. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy[J]. Radiat Oncol, 2014, 9:147. .
[287]
GriffioenGH, ToguriD, DaheleM, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors[J]. Lung Cancer, 2013, 82(1):95-102. .
[288]
中国抗癌协会肺癌专业委员会. 非小细胞肺癌孤立性转移处理共识[J]. 循证医学, 2007, 7(2):109-112. .
[289]
IyengarP, KavanaghBD, WardakZ, et al. Phase Ⅱ trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2014, 32(34):3824-3830. .
[290]
LadT, PiantadosiS, ThomasP, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J]. Chest, 1994, 106(6 Suppl):320S-323S. .
[291]
ShepherdFA, EvansWK, FeldR, et al. Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung[J]. J Clin Oncol, 1988, 6(5):832-838. .
[292]
TsuchiyaR, SuzukiK, IchinoseY, et al. Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group trial (JCOG9101)[J]. J Thorac Cardiovasc Surg, 2005, 129(5):977-983. .
[293]
SchreiberD, RineerJ, WeedonJ, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?[J]. Cancer, 2010, 116(5):1350-1357. .
[294]
WongAT, RineerJ, SchwartzD, et al. Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the national cancer database[J]. J Thorac Oncol, 2016, 11(2):242-248. .
[295]
TakadaM, FukuokaM, KawaharaM, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104[J]. J Clin Oncol, 2002, 20(14):3054-3060. .
[296]
TurrisiAT, KimK, BlumR, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340(4):265-271. .
[297]
SchildSE, BonnerJA, ShanahanTG, et al. Long-term results of a phase Ⅲ trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2004, 59(4):943-951. .
[298]
ChoiNC, HerndonJE, RosenmanJ, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer[J]. J Clin Oncol, 1998, 16(11):3528-3536. .
[299]
MillerKL, MarksLB, SibleyGS, et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 56(2):355-359. .
[300]
RoofKS, FidiasP, LynchTJ, et al. Radiation dose escalation in limited-stage small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 57(3):701-708. .
[301]
BogartJA, HerndonJE, LyssAP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808[J]. Int J Radiat Oncol Biol Phys, 2004, 59(2):460-468. .
[302]
SundstrømS, BremnesRM, KaasaS, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase Ⅲ trial with 5 years′ follow-up[J]. J Clin Oncol, 2002, 20(24):4665-4672. .
[303]
RossiA, Di MaioM, ChiodiniP, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data[J]. J Clin Oncol, 2012, 30(14):1692-1698. .
[304]
FriedDB, MorrisDE, PooleC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer[J]. J Clin Oncol, 2004, 22(23):4837-4845. .
[305]
StinchcombeTE, GoreEM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms[J]. Oncologist, 2010, 15(2):187-195. .
[306]
AupérinA, ArriagadaR, PignonJP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group[J]. N Engl J Med, 1999, 341(7):476-484. .
[307]
HornL, MansfieldAS, SzczęsnaA, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229. .
[308]
GoldmanJW, DvorkinM, ChenY, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1):51-65. .
[309]
WangJ, ZhouC, YaoW, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(6):739-747. .
[310]
ChengY, HanL, WuL, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial[J]. JAMA, 2022, 328(12):1223-1232. .
[311]
SpigelDR, TownleyPM, WaterhouseDM, et al. Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial[J]. J Clin Oncol, 2011, 29(16):2215-2222. .
[312]
OkamotoH, WatanabeK, NishiwakiY, et al. Phase Ⅱ study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer[J]. J Clin Oncol, 1999, 17(11):3540-3545. .
[313]
NodaK, NishiwakiY, KawaharaM, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):85-91. .
[314]
ChengY, FanY, LiuX, et al. Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer[J]. Oncol Lett, 2019, 17(5):4701-4709. .
[315]
WeissJM, CsosziT, MaglakelidzeM, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial[J]. Ann Oncol, 2019, 30(10):1613-1621. .
[316]
JeremicB, ShibamotoY, NikolicN, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study[J]. J Clin Oncol, 1999, 17(7):2092-2099. .
[317]
YeeD, ButtsC, ReimanA, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J]. Radiother Oncol, 2012, 102(2):234-238. .
[318]
SlotmanBJ, van TinterenH, PraagJO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42. .
[319]
JeremicB, CasasF, WangL, et al. Radiochemotherapy in extensive disease small cell lung cancer ED-SCLC[J]. Front Radiat Ther Oncol, 2010, 42:180-186. .
[320]
SlotmanB, Faivre-FinnC, KramerG, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer[J]. N Engl J Med, 2007, 357(7):664-672. .
[321]
TakahashiT, YamanakaT, SetoT, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(5):663-671. .
[322]
MickeP, FaldumA, MetzT, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?[J]. Lung Cancer, 2002, 37(3):271-276. .
[323]
ChengY, LiuXQ, FanY, et al. Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer[J]. Future Oncol, 2016, 12(6):789-799. .
[324]
Le PéchouxC, DunantA, SenanS, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial[J]. Lancet Oncol, 2009, 10(5):467-474. .
[325]
SlotmanBJ, MauerME, BottomleyA, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase Ⅲ randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups[J]. J Clin Oncol, 2009, 27(1):78-84. .
[326]
von PawelJ, SchillerJH, ShepherdFA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol, 1999, 17(2):658-667. .
[327]
O′BrienME, CiuleanuTE, TsekovH, et al. Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J]. J Clin Oncol, 2006, 24(34):5441-5447. .
[328]
EckardtJR, von PawelJ, PujolJL, et al. Phase Ⅲ study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer[J]. J Clin Oncol, 2007, 25(15):2086-2092. .
[329]
YangS, ZhangZ, WangQ. Emerging therapies for small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1):47. .
[330]
DerksJL, HendriksLE, BuikhuisenWA, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview[J]. Eur Respir J, 2016, 47(2):615-624. .
[331]
MastersGA, TeminS, AzzoliCG, et al. Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2015, 33(30):3488-3515. .
[332]
AbsengerG, TerzicJ, BezanA. ASCO update: lung cancer[J]. Memo, 2017, 10(4):224-227. .
[333]
ColtHG, MurguSD, KorstRJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5Suppl):e437S-e454S. .
[334]
LouF, HuangJ, SimaCS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance[J]. J Thorac Cardiovasc Surg, 2013, 145(1):75-81; discussion 81-82. .
[335]
CrabtreeTD, PuriV, ChenSB, et al. Does the method of radiologic surveillance affect survival after resection of stage Ⅰ non-small cell lung cancer?[J]. J Thorac Cardiovasc Surg, 2015, 149(1):45-52, 53.e1-3. .
[336]
BackhusLM, FarjahF, LiangCK, et al. Imaging surveillance and survival for surgically resected non-small-cell lung cancer[J]. J Surg Res, 2016, 200(1):171-176. .
[337]
WesteelV, LebitasyMP, MercierM, et al. [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer][J]. Rev Mal Respir, 2007, 24(5):645-652. .
[338]
TakenakaD, OhnoY, KoyamaH, et al. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients[J]. Eur J Radiol, 2010, 74(3):458-464. .
[339]
CuaronJ, DunphyM, RimnerA. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer[J]. Front Oncol, 2012, 2:208. .
[340]
MamonHJ, YeapBY, JännePA, et al. High risk of brain metastases in surgically staged ⅢA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation[J]. J Clin Oncol, 2005, 23(7):1530-1537. .
[341]
HuY, McMurryTL, IsbellJM, et al. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality[J]. J Thorac Cardiovasc Surg, 2014, 148(5):2261-2267.e1. .
[342]
PezziCM, MallinK, MendezAS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality[J]. J Thorac Cardiovasc Surg, 2014, 148(5):2269-2277. .
[343]
Janssen-HeijnenM, van ErningFN, De RuysscherDK, et al. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis[J]. Ann Oncol, 2015, 26(5):902-907. .
[344]
JohnsonBE. Second lung cancers in patients after treatment for an initial lung cancer[J]. J Natl Cancer Inst, 1998, 90(18):1335-1345. .
[345]
RipleyRT, McMillanRR, SimaCS, et al. Second primary lung cancers: smokers versus nonsmokers after resection of stage Ⅰ lung adenocarcinoma[J]. Ann Thorac Surg, 2014, 98(3):968-974. .
[346]
HamajiM, AllenMS, CassiviSD, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2013, 145(3):683-690; discussion 690-691. .
[347]
SprattDE, WuAJ, AdeseyeV, et al. Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance[J]. Clin Lung Cancer, 2016, 17(3):177-183.e2. .
[348]
HuangK, SenthiS, PalmaDA, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer[J]. Radiother Oncol, 2013, 109(1):51-57. .
[349]
PeulenH, MantelF, GuckenbergerM, et al. Validation of high-risk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 96(1):134-141. .
[350]
NeriS, TakahashiY, TerashiT, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers[J]. J Thorac Oncol, 2010, 5(12):2003-2007. .
[351]
TairaN, KawabataT, IchiT, et al. Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells[J]. Ann Thorac Surg, 2014, 97(6):2167-2171. .
[352]
HamajiM, ChenF, MatsuoY, et al. Treatment and prognosis of isolated local relapse after stereotactic body radiotherapy for clinical stage Ⅰ non-small-cell lung cancer: importance of salvage surgery[J]. J Thorac Oncol, 2015, 10(11):1616-1624. .
[353]
DickhoffC, DaheleM, PaulMA, et al. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer[J]. Lung Cancer, 2016, 94:108-113. .
[354]
VerstegenNE, MaatAP, LagerwaardFJ, et al. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer[J]. Radiat Oncol, 2016, 11(1):131. .
[355]
中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022版)[J]. 中华医学杂志, 2022, 102(23):1706-1740. .